Sign In
Buy LFCR
$4.42
+0.0600 (+1.38%)
At Close: Jul 31, 2026
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect
10:00am, Sunday, 22'nd Dec 2024
NEW YORK, NY / ACCESSWIRE / December 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company")
Lifecore Biomedical to Report Financial Results for Second Quarter of Fiscal 2025 on January 2, 2025
04:05pm, Thursday, 19'th Dec 2024
CHASKA, Minn., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today a
Development Services Span Tech Transfer, Process Assessment and Method Validation for Fill and Finish of NRS-033 for Planned Phase 2 Trial
NEW YORK, NY / ACCESSWIRE / December 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company")
NEW YORK, NY / ACCESSWIRE / December 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company")
Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Investors to Inquire about Securities Investigation
03:00pm, Wednesday, 11'th Dec 2024
NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company")
Lifecore Biomedical: An Interesting CDMO Pure Play
10:40am, Sunday, 01'st Dec 2024
Lifecore, a leading CDMO, specializes in sterile injectable pharmaceuticals and is poised to benefit from the growing CDMO market and potential GLP-1 opportunities. The company is doubling production
Lifecore Biomedical Amends and Extends Revolving Credit Facility with BMO
04:05pm, Tuesday, 26'th Nov 2024
Three-Year Term Extension Combined with Simplification and Reduction of Interest Rates Helps Further Strengthen Company's Balance Sheet and Overall Financial Position
Lifecore Biomedical Hosts Virtual Investor Day
04:17pm, Thursday, 21'st Nov 2024
CHASKA, Minn., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today a
Lifecore Biomedical to Present at Stephens Annual Investment Conference
04:05pm, Tuesday, 12'th Nov 2024
CHASKA, Minn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today a
Lifecore Biomedical to Host Virtual Investor Day Prior to Market Open on November 21, 2024
07:00am, Thursday, 07'th Nov 2024
CHASKA, Minn., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today a
Lifecore Biomedical Appoints Thomas Guldager as Vice President, Operations
07:00am, Monday, 04'th Nov 2024
Brings Strong Background in Pharmaceutical Manufacturing Operations and Finance to Help Drive Performance and Productivity
SAN DIEGO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP (www.johnsonfistel.com), a shareholder rights law firm, announces its continuing investigation of whether certain directors and officer
Lifecore Biomedical, Inc. (LFCR) Q1 2025 Earnings Call Transcript
10:59am, Friday, 04'th Oct 2024
Lifecore Biomedical, Inc. (NASDAQ:LFCR ) Q1 2025 Earnings Call Transcript October 4, 2024 8:30 AM ET Company Participants Stephanie Diaz - Manager of IR Paul Josephs - President and CEO Ryan Lake - CF
Lifecore Biomedical Reports First Quarter of Fiscal 2025 Financial Results and Provides Corporate Update
07:30am, Friday, 04'th Oct 2024
-- Recorded Revenues of $24.7 Million for Q1 Fiscal 2025 -- -- Signed Multiple New Business Agreements with New and Existing Customers --
